Axalimogene filolisbac: Phase II started

Advaxis began the 2-stage, open-label, U.S. Phase II FAWCETT trial to evaluate 1x10 9 colony forming unit (CFU) doses of axalimogene filolisbac every 3 weeks for up to 2 years in about 55 patients who...